STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.
Kymera Therapeutics, a Massachusetts biotech, is set to announce key trial results for its eczema-focused drug, KT-621, in the coming weeks. This data could mark a pivotal moment as it competes with Sanofi and Regeneron's top-selling immunology drug, Dupixent. The upcoming readout from Kymera's mid-stage clinical trial is described by analysts at Jefferies as "one of the most impactful I&I readouts this year," potentially shaping the future of eczema treatment and Kymera's broader aspirations to address other immunological diseases.
Analysts project that if successful, the drug's sales could soar to nearly $4 billion by 2035, with more than $3 billion coming from eczema alone.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
